Clinical trial
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
NCT00285857 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00285857 |
|---|---|
| Title | Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention |
| Official title | A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer |
| Lead sponsor | Stanford University, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Lovastatin |
| Enrollment | 30 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Feb 2, 2006 |
| Last update posted | Mar 9, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: